Ask AI
ProCE Banner Events

A Unique PD-1 Inhibitor for the 1L Treatment of Adult Patients with ESCC and GC/GEJC

Join us for a 30-minute discussion on the role of TEVIMBRA (tislelizumab-jsgr), an approved immunotherapy specifically designed to optimize PD-1 binding and deliver more robust T-cell activation. Medical oncologists and other healthcare professionals are invited to this overview of the latest clinical trial data, focusing on TEVIMBRA's unique design, efficacy and safety profile, and dosing information.

Key Takeaways

  • Review the current treatment outcomes and unmet need in ESCC and GC/GEJC.
  • Understand clinical utility and differentiation of TEVIMBRA (tislelizumab) in ESCC and GC/GEJC based on clinical data
Time and location

Wednesday, January 14, 2026

12:15 PM - 12:45 PM Eastern Time (ET)

Virtual

Acknowledgement

Sponsored By

BeOne Medicines

BeOne Medicines

Additional Information

TEVIMBRA Prescribing Information